Feeds:
Posts
Comments

Posts Tagged ‘Actelion’

J&J found not liable in Motrin case – Johnson & Johnson on Thursday won a lawsuit brought by the family of an 11-year-old girl who became blind after using the drug Children’s Motrin in 2003…more

Preemption reversed? – US District Court Judge David Hamilton has reversed his prior opinion in which he had dismissed a Paxil suicide case based on preemption, which says that FDA approval supercedes state law claims challenging safety, efficacy, or labeling. The FDA and drugmakers argue preemption exists by maintaining agency actions are the final word on safety and effectiveness. The case is now re-opened…more

Teva pays Barr tab – The world’s largest maker of generic drugs is expanding once again. Teva has agreed to pay $66.50, or a total of $7.46 billion plus the assumption of net debt of approximately $1.5 billion…more

AZ and Ethical pharma – AstraZeneca is training staff in a new Code of Conduct that aims to ensure employees at all levels and locations act appropriately. The Code was introduced in May and covers a number issues, including interactions with healthcare professionals, conflicts of interest and the ethics of R&D. It goes further than the recently revised EFPIA or PhRMA rules and explicitly spells out dos and don’ts on additional issues, such as political donations and insider trading…more

You’ve heard about the HR helicopter? Some folks take this literally.

PhRMA says, “Bag the Schwag” – A ubiquitous element of pharmaceutical marketing is scheduled to vanish next January 1, as the revised marketing code of the Pharmaceutical Research and Manufacturers of America goes into effect. Gone will be the non-educational freebies—the pens, pads, mugs, toys, and miscellaneous tchotchkes?that pharma companies distribute by the carload…more. And more here from Pharmalot.

The Washington D.C. rules and regs for pharma sales reps.

Glaxo to pay billions for a good night’s sleep – The drugmaker has agreed to pay that much for the licensing rights to Actelion’s investigational drug, almorexant…more

BI cutting neuro sales force – The neurology sales team, which peddles Aggrenox to neurologists for treating transient ischemic attacks and strokes, met last week in Chicago, where BI managers told them they are going to restructure…more

Zemanta Pixie

Read Full Post »

Fresh news from the ADA (American Diabetes Association):

Takeda’s alogliptin shows impressive results – Takeda Pharmaceutical Co Ltd’s  experimental diabetes drug alogliptin significantly lowers blood sugar alone and in combination with other common therapies, according to research presented on Saturday…more More detailed data here.

Sanofi’s experimental injectable diabetes drug shows promise – An experimental injectable type 2 diabetes drug being developed by Sanofi-Aventis SA was well tolerated and significantly improved blood sugar control compared with a placebo, according to data presented on Saturday…more

Head-to-head study of Byetta with an experimental Novo drug…very interesting – Novo Nordisk’s experimental type 2 diabetes drug, liraglutide, was superior in controlling blood sugar in a clinical trial to Eli Lilly and Co and Amylin Pharmaceuticals Inc’s Byetta, the Danish company said on Friday…more

Forbes.com has a bunch of follow-up articles growing out of the recent ASCO meeting:

:: Cancer Revolution, or Me-too Mess? Over the next decade, drug companies could either start selling more cancer drugs than at any time in history or face the biggest string of clinical failures ever…more

:: Cancer Drug Winners and LosersThe data presented at ASCO can have a huge impact both on the share prices of drug firms and on the long-term sales of their medicines. Here’s a roundup of the most important drug studies from the meeting and a look at how they will affect the companies involved…more

:: Novartis Steals the ShowNovartis is emerging as the surprise winner at this year’s annual meeting of the American Society of Clinical Oncology, the year’s biggest cancer conference…more

:: Can Cancer Cure Pfizer?The recovery of Pfizer, the world’s biggest pharmaceutical company, rests largely on how well Nicholson, 53, can get cancer-fighting drugs out of its research labs and into doctors’ offices…more

:: And, if you want the real short-form bullet-point summary, here’s the high-level ASCO overview from Pharma Exec.

In other news….

Crestor Gaining Market Share – AstraZeneca Plc’s cholesterol drug Crestor is gaining market share in the highly competitive U.S. market, following recent encouraging data and problems faced by rival medicine Vytorin…more

Arthritis Drugs Cause Concern – The U.S. Food and Drug Administration warned American consumers on Wednesday that it is looking into side effects of a class of arthritis drugs that could cause cancer in children…more

Novartis Buying into Antibiotics – Novartis said it’s going to pay $100 million up front, plus as much as $300 million more, for Protez Pharmaceuticals. Protez makes PZ-601, an antibiotic in Phase II development against potentially fatal drug-resistant infections, including the MRSA and ESBL strains…more

Actelion: Who’s circling? -Big drugmakers want to do a deal with Switzerland’s Actelion Ltd — the question is will it be a $1 billion-plus drug marketing alliance or a $7 billion-plus takeover?…more (hat tip: Pharmagossip)

Sexual Harassment and Drug Reps: Watch your Steps, Folks: (from PharmaGossip) Workers at pharmaceutical giant Eli Lilly may want to lay off the Cialis – a longtime saleswoman says she was canned after complaining about her boss’ sexist rants and the come-ons of her sales partner…more

Velcade: a cancer treatment with some potential for lupus? - Velcade, a drug used to treat cancer, might also work against the chronic autoimmune disease lupus, German researchers said on Sunday…more

And…here’s the weekly blog/news summary from Chris Truelove at PharmaLive.

Zemanta Pixie

Read Full Post »

Follow

Get every new post delivered to your Inbox.

Join 27 other followers